• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: SDZNY )

    42.35 +0.39 (+0.93%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 128,094
    Open 41.80
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 41.96
    Today's Range 41.77 - 42.37
    52wk Range 25.71 - 42.11
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
    From Sandoz Group
    Via GlobeNewswire
    3 Spinoff Stocks You Should Buy Now: July 2024
    Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
    Via InvestorPlace

    Performance

    YTD
    +32.84%
    +32.84%
    1 Month
    +18.13%
    +18.13%
    3 Month
    +26.00%
    +26.00%
    6 Month
    +23.98%
    +23.98%
    1 Year
    +59.69%
    +59.69%

    More News

    Read More
    Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
    Via MarketBeat
    Upcoming Stock Spinoffs: Should You Pounce or Pass?
    Via InvestorPlace
    FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
    From Sandoz Group
    Via GlobeNewswire
    Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
    From Sandoz Group
    Via GlobeNewswire
    Sandoz reports first quarter 2024 sales
    From Sandoz Group
    Via GlobeNewswire
    Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
    From Sandoz Group
    Via GlobeNewswire
    Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
    From Sandoz Group
    Via GlobeNewswire
    Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
    From Sandoz Group
    Via GlobeNewswire
    Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
    From Sandoz Group
    Via GlobeNewswire
    Sandoz reports fourth quarter 2023 sales and full-year 2023 results
    From Sandoz Group
    Via GlobeNewswire
    Sandoz receives FDA approval for first and only denosumab biosimilars
    From Sandoz Group
    Via GlobeNewswire
    Sandoz announces nominations to the Board of Directors and leadership change
    From Sandoz Group
    Via GlobeNewswire
    Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
    From Sandoz Group
    Via GlobeNewswire
    Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
    Via Benzinga
    Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
    From Sandoz Group
    Via GlobeNewswire
    Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
    Via Benzinga
    Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
    Via Benzinga
    Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
    Via Benzinga
    Topics Earnings
    Exposures Financial
    Eli Lilly, McKesson, Novartis Flash Promising Chart Action
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.